ABIONYX Pharma Repays €1.75 Million in Bonds, with 30% in New Shares

A Repayment of €1.75 Million Settled in Cash and Shares

ABIONYX Pharma announced on October 2, 2026 a partial repayment of the principal of bonds subscribed by Fenja Capital II A/S, for an amount of €1.75 million. Approximately 70% of this amount, or €1,226,206.34, is settled in cash by October 2, 2026 at the latest, with accrued interest on the period being paid simultaneously in cash. The remaining approximately 30%, or €523,793.66, is settled by the issuance of 331,299 new ordinary shares for the benefit of Fenja, at a subscription price of €1.58103 per share. Following this repayment, the principal amount outstanding on the bonds stands at €8.25 million. The bond financing had been concluded on May 26, 2026 in the form of simple unsecured and non-convertible bonds, for an amount that could reach €14 million.

A Capital Increase Reserved and Paid through Compensation of Receivables

The issuance of new shares corresponds to a capital increase with elimination of preferential subscription rights, reserved for Fenja, in accordance with the 21st resolution of the combined general meeting of June 30, 2026 and implemented by the board of directors on October 1, 2026. The subscription price is fully paid through compensation with receivables held by Fenja as payment for repayment, so that the issuance will result in no proceeds. Settlement-delivery and admission to trading on Euronext Paris are scheduled for or around October 6, 2026. The issuance results in a dilution of approximately 0.77% of the share capital on an undiluted basis. As of June 30, 2026, the company had cash, cash equivalents and short-term investments of €26.9 million. Following this early repayment, the projected cash horizon remains unchanged, until the fourth quarter of 2028 based on current operational assumptions.